Montelukast Kern Pharma (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Kern Pharma, is a leukotriene receptor antagonist presented as a tablet for oral use. It is used to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in patients requiring long‑term control. GNH USA supplies Montelukast Kern Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to reduce airway inflammation and bronchoconstriction. - Asthma: improves long‑term control and reduces exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea: occasional upset stomach. - Dizziness: brief episodes of light‑headedness. - Fatigue: mild tiredness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or throat. - Stevens‑Johnson syndrome: severe skin reaction. - Hepatic injury: elevated liver enzymes. - Anaphylaxis: life‑threatening allergic response. - Mood changes: depression or suicidal thoughts. - Rash with eosinophilia: hypersensitivity skin eruption.

Before prescribing Montelukast, clinicians should consider several safety aspects. - Neuropsychiatric monitoring: watch for mood changes or suicidal thoughts. - Hepatic function: use caution in patients with liver impairment. - Hypersensitivity: avoid in individuals with known allergy to montelukast or excipients. - Asthma control: ensure stable disease before discontinuation. - Drug review: assess concomitant medications that affect CYP3A4. - Store at room temperature: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase montelukast exposure. - Ritonavir (HIV protease inhibitor): can raise plasma levels. - Hypersensitivity‑inducing agents: concurrent use may heighten allergic risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, phenobarbital, carbamazepine): may reduce effectiveness. - Warfarin: potential alteration of INR, requiring monitoring. - Beta‑agonists: possible reduction in bronchodilator response.